HC Wainwright Predicts Harrow's Q4 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities researchers at HC Wainwright issued their Q4 2024 earnings per share estimates for Harrow in a report issued on Thursday, February 6th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $57.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.20) EPS.

Separately, B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a report on Wednesday, December 4th.

Harrow Stock Performance

Shares of NASDAQ:HROW traded up $1.97 during trading on Monday, reaching $31.91. The company had a trading volume of 268,068 shares, compared to its average volume of 332,030. The stock's fifty day moving average price is $34.25 and its 200 day moving average price is $39.87. Harrow has a fifty-two week low of $9.30 and a fifty-two week high of $59.23. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -33.95 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Institutional Trading of Harrow

Several large investors have recently bought and sold shares of the company. First Turn Management LLC purchased a new stake in shares of Harrow in the third quarter valued at $14,683,000. JPMorgan Chase & Co. lifted its position in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Harrow in the third quarter valued at $8,572,000. Charles Schwab Investment Management Inc. lifted its position in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after acquiring an additional 166,602 shares in the last quarter. Finally, Braidwell LP lifted its position in shares of Harrow by 47.9% in the third quarter. Braidwell LP now owns 439,638 shares of the company's stock valued at $19,766,000 after acquiring an additional 142,450 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.